Semaglutide Research for Kidney Disease
An evidence-based overview of research examining Semaglutide in the context of kidney disease. This page synthesizes findings from peer-reviewed literature.
Research Summary
The FLOW trial (N=3,533) demonstrated that semaglutide reduces kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. This is the first GLP-1 receptor agonist to show kidney-specific outcomes benefit. The trial was stopped early for efficacy. Semaglutide reduced the composite endpoint of kidney failure, sustained 50% eGFR decline, and kidney-related death. Benefits were consistent across baseline kidney function levels. The mechanism of kidney protection may involve improved glycemic control, blood pressure reduction, weight loss, and reduced inflammation. Semaglutide is now considered for kidney protection in addition to its metabolic and cardiovascular benefits.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Kidney Disease
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.